Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer a methodological protocol to a study using five European databases

Gincy George (1) , Lucie-Marie Scailteux (2, 3) , Hans Garmo (1) , Frédéric Balusson (2) , Christopher Cardwell (4) , Greet de Coster , Harlinde de Schutter , Josephina G Kuiper , Úna Mcmenamin (4) , Julie Verbeeck , Mieke van Hemelrijck (1)

1 King‘s College London
2 REPERES - Recherche en Pharmaco-épidémiologie et Recours aux Soins
3 CHU Pontchaillou [Rennes]
4 QUB - Queen's University [Belfast]

Keywords: GnRH agonists; GnRH antagonists; cardiovascular disease; Prostate cancer; real world evidence

Domains: Life Sciences [q-bio]; Pharmaceutical sciences; Pharmacology; Life Sciences [q-bio]; Santé publique et épidémiologie

Gincy George, Lucie-Marie Scailteux, Hans Garmo, Frédéric Balusson, Christopher Cardwell, et al.. Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer a methodological protocol to a study using five European databases. Fundamental & Clinical Pharmacology, 2019, 33 (4), pp.479-499. ⟨10.1111/fcp.12454⟩. ⟨hal-02055724⟩